Back to top
more

Pharming Group (PHAR)

(Delayed Data from NSDQ)

$10.96 USD

10.96
23,035

-0.15 (-1.35%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Buy Stocks for August 1st

by Zacks Equity Research

ROKU, PHAR, ASC, META and ARI have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2025.

Zacks Equity Research

Best Momentum Stocks to Buy for July 25th

by Zacks Equity Research

RVLV, PHAR and AMZN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 25, 2025.

Zacks Equity Research

New Strong Buy Stocks for July 25th

by Zacks Equity Research

PHIN, MBWM, THC, RVLV and PHAR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2025.

Zacks Equity Research

Best Momentum Stocks to Buy for July 17th

by Zacks Equity Research

PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.

Zacks Equity Research

New Strong Buy Stocks for July 17th

by Zacks Equity Research

PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last?

by Zacks Equity Research

Novavax (NVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?

by Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up

by Zacks Equity Research

Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.

Zacks Equity Research

Why Earnings Season Could Be Great for Pharming Group (PHAR)

by Zacks Equity Research

Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

by Zacks Equity Research

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Pharming Group N.V. Sponsored ADR (PHAR) and POINT Biopharma Global Inc. (PNT) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.